Long-term response with sunitinib for metastatic renal cell carcinoma - 20/08/11
Doi : 10.1016/j.urology.2006.03.042
Ellen A. Ronnen a, G. Varuni Kondagunta a, Michelle S. Ginsberg c, Paul Russo b, Robert J. Motzer a, ⁎ 
a Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, New York
b Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York
c Department of Medicine, Cornell University Joan and Sanford I. Weill Medical College, Ithaca, New York
Address for correspondence: Robert J. Motzer, M.D., Department of Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021Abstract |
A 65-year-old man with metastatic renal cell carcinoma developed progressive disease after treatment with interferon-⍺. He began treatment with sunitinib, a multitargeted tyrosine kinase inhibitor, on clinical trial. The patient achieved a partial response after two cycles of therapy, with a durable response continuing after 2 years of treatment. This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma.
Le texte complet de cet article est disponible en PDF.Plan
| This study was funded in part by Pfizer, Incorporated, New York, New York. |
© 2006
Elsevier Inc. Tous droits réservés.
Vol 68 - N° 3
P. 672.e19-672.e20 - septembre 2006 Retour au numéro
Article précédent
- Bilateral testicular masses: An unusual presentation of neuroblastoma
- Brian L. Gallagher, Rajeev Vibhakar, Simon Kao, Christopher S. Cooper
- Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney
- Marcus L. Quek, Zane Basrawala, Christopher McClung, Robert C. Flanigan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?